We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
Read MoreHide Full Article
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 million, representing a decline of 47.2% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Moderna metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenue- Net Product sales' to reach $81.42 million. The estimate indicates a change of -55.8% from the prior-year quarter.
The consensus estimate for 'Revenue- Other revenue' stands at $25.13 million. The estimate indicates a year-over-year change of -55.9%.
The consensus among analysts is that 'Product sales- United States' will reach $28.31 million. The estimate points to a change of -82.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Product sales- Rest of world' of $42.95 million. The estimate points to a change of +95.2% from the year-ago quarter.
Over the past month, Moderna shares have recorded returns of +22.9% versus the Zacks S&P 500 composite's +3.6% change. Based on its Zacks Rank #3 (Hold), MRNA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Curious about Moderna (MRNA) Q2 Performance? Explore Wall Street Estimates for Key Metrics
The upcoming report from Moderna (MRNA - Free Report) is expected to reveal quarterly loss of -$2.99 per share, indicating an increase of 10.2% compared to the year-ago period. Analysts forecast revenues of $127.17 million, representing a decline of 47.2% year over year.
The consensus EPS estimate for the quarter has undergone a downward revision of 1.4% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Moderna metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenue- Net Product sales' to reach $81.42 million. The estimate indicates a change of -55.8% from the prior-year quarter.
The consensus estimate for 'Revenue- Other revenue' stands at $25.13 million. The estimate indicates a year-over-year change of -55.9%.
The consensus among analysts is that 'Product sales- United States' will reach $28.31 million. The estimate points to a change of -82.5% from the year-ago quarter.
The collective assessment of analysts points to an estimated 'Product sales- Rest of world' of $42.95 million. The estimate points to a change of +95.2% from the year-ago quarter.
View all Key Company Metrics for Moderna here>>>Over the past month, Moderna shares have recorded returns of +22.9% versus the Zacks S&P 500 composite's +3.6% change. Based on its Zacks Rank #3 (Hold), MRNA will likely exhibit a performance that aligns with the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .